Scotoma Clinical Trial
Official title:
Validation of a Smartphone-Based Flicker Fusion Test
The purpose of this project is to validate a quick, easy-to-use and administer smartphone flicker fusion test. The app (called eyeFusion) can potentially be used to easily and quickly collect critical flicker fusion measurements on patients admitted with optic disorders as part of the clinical care process.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | January 1, 2028 |
Est. primary completion date | January 1, 2028 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: Control - Age matched 18-80 years of age. - Healthy normal controls with no known eye disorders. Exclusion Criteria: - Scotoma or any other ocular disorder Inclusion Criteria - Patients - Age 18-80 - Clinically associated scotoma Exclusion Criteria - Patients -Any other ocular disorder |
Country | Name | City | State |
---|---|---|---|
United States | University of Iowa | Iowa City | Iowa |
Lead Sponsor | Collaborator |
---|---|
Randy Kardon |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Assess Validity of the test construct measuring flicker fusion thresholds. | The smartphone app developed is a flicker fusion that presents the subject with a series of stimuli consisting of a flickering pattern of bars above or below a static rectangle. The study will assess the validity of the test construct in measuring flicker fusion thresholds, and serve as a foundation for further iterative designs of the app and future validation and characterization studies. | 1/1/2020 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00921427 -
The Use of Transcranial Direct Current Stimulation (TDCS) to Enhance the Rehabilitative Effect of Vision Restoration Therapy
|
Phase 0 | |
Completed |
NCT01418820 -
Paraorbital-Occipital Alternating Current Stimulation Therapy of Patients With Post-Chiasmatic Lesions
|
Phase 2 |